As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932].
Following communications with the company the timelines for this appraisal have been revised. The appraisal is now anticipated to begin during early January 2023 when we will write to you about how you can get involved.